A Phase 1, single ascending dose clinical study of CIN-109
Latest Information Update: 29 Sep 2021
At a glance
- Drugs CIN 109 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- 29 Sep 2021 New trial record
- 22 Sep 2021 According to CinFina media release, it has signed an agreement with Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to acquire exclusive global rights to GDF-15 and PYY analogs (CIN-109 and CIN-110, respectively)
- 22 Sep 2021 According to CinFina media release, In a Phase 1, single ascending dose clinical study, CIN-109 was well tolerated, demonstrating decreases in food intake.